Medline Industries v. C. R. Bard: Foley Kit Patent Dispute Sent to Mediation
Medline Industries, LP filed a patent infringement action against C. R. Bard, Inc. in the Northern District of Georgia, asserting six patents covering Foley catheter insertion kit technology including the SureStep Foley Kit. After more than 1,243 days of litigation and contested claim construction proceedings, the court referred the parties to private mediation.
Six-patent Foley catheter dispute referred to mediation after claim construction
Medline Industries, LP filed suit against C. R. Bard, Inc. on September 25, 2020 in the U.S. District Court for the Northern District of Georgia (Case No. 1:20-cv-03981), presided over by Judge J. P. Boulee. Medline asserted six patents — US7278987B2, US3329261A, US3978983A, US8678190B2, US8448786B2, and US8631935B2 — in an infringement action centred on Foley catheter insertion kit technology, with Bard’s SureStep Foley Kit identified as the accused product.
After more than three years of proceedings that included contested claim construction briefing and a Report and Recommendation from a magistrate judge, Judge Boulee overruled objections filed by both parties and adopted the Report and Recommendation as the court’s order. Critically, the court did not dismiss the case; instead, it found that issues had been sufficiently narrowed to make private mediation productive. The case was administratively closed and removed from the active docket, with the outstanding claim construction issue stayed pending the outcome of mediation.
The court directed mediation to conclude no later than May 20, 2024, with a status report due May 23, 2024. Administrative closure of this kind is a procedural mechanism — not a final judgment — and the case would be restored to the active docket if mediation failed. The Basis of Termination is recorded as ‘Case Stayed,’ suggesting the public record does not yet confirm whether a settlement was ultimately reached. The length of litigation, the scale of the legal teams deployed on both sides, and the six-patent assertion all suggest commercially significant stakes in the Foley catheter market.
Filing to settlement in 1243 days
1,243 days — over three years from filing to administrative closure
Case administratively closed and referred to private mediation
Administrative closure is not a final judgment
Administrative closure differs from dismissal or a final verdict. The court removes the case from its active docket for efficiency, but retains jurisdiction. If mediation does not resolve the dispute, either party may move to reopen. For IP professionals tracking this dispute, the absence of a final judgment means all asserted claims remain live and no estoppel or res judicata effect has attached.
Case remains legally liveContested claim construction preceded mediation referral
The court adopted a magistrate’s Report and Recommendation on claim construction after overruling objections from both sides, suggesting genuine interpretive disputes over the scope of the six asserted patents. Claim construction outcomes can decisively shift infringement and validity positions; the narrowing of issues that followed may have altered each party’s litigation calculus and made settlement more attractive without requiring a full trial.
Claim scope narrowedEven split on mediator costs — no fee-shifting signal
The court’s direction to split mediator costs evenly is neutral and does not indicate that either party was found to have behaved unreasonably. No attorneys’ fees award or cost-shifting order was made at this stage. This is consistent with standard practice when a court orders mediation before final adjudication, and should not be read as a ruling on the merits of either party’s position.
No adverse cost rulingCourt set a hard deadline: mediation by May 20, 2024
Judge Boulee imposed a specific deadline — mediation to conclude by May 20, 2024, with a status report due May 23, 2024. This tight window, combined with the outstanding claim construction stay, created strong incentive for both parties to negotiate seriously. The fact that the Basis of Termination is recorded as ‘Case Stayed’ rather than ‘Settled’ means the public record does not confirm whether the mediation was ultimately successful.
Outcome unconfirmed publiclyFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Medline Industries | Company | Medical supply manufacturer and distributor — holder of US7278987B2 and 5 further Foley kit patentsSearch in Eureka ↗ |
| Defendant | C. R. Bard, Inc. | Company | C. R. Bard, Inc. — medical device maker and maker of the accused SureStep Foley Kit productSearch in Eureka ↗ |
| Plaintiff counsel | Courtney Elizabeth Cronin | Attorney | Counsel for Medline IndustriesSearch in Eureka ↗ |
| Plaintiff counsel | Daniel Arthur Kent | Attorney | Counsel for Medline IndustriesSearch in Eureka ↗ |
| Plaintiff counsel | Ethan M. Knott | Attorney | Counsel for Medline IndustriesSearch in Eureka ↗ |
| Plaintiff counsel | Gwen Hohcman Stewart | Attorney | Counsel for Medline IndustriesSearch in Eureka ↗ |
| Plaintiff counsel | Henry D. Fellows, Jr. | Attorney | Counsel for Medline IndustriesSearch in Eureka ↗ |
| Plaintiff counsel | Nathaniel C. Love | Attorney | Counsel for Medline IndustriesSearch in Eureka ↗ |
| Plaintiff counsel | Stephanie P. Koh | Attorney | Counsel for Medline IndustriesSearch in Eureka ↗ |
| Plaintiff counsel | Thomas D. Rein | Attorney | Counsel for Medline IndustriesSearch in Eureka ↗ |
| Defendant counsel | Athena Dalton | Attorney | Counsel for C. R. Bard, Inc.Search in Eureka ↗ |
| Defendant counsel | Bianca A. Fox | Attorney | Counsel for C. R. Bard, Inc.Search in Eureka ↗ |
| Defendant counsel | Dawn David | Attorney | Counsel for C. R. Bard, Inc.Search in Eureka ↗ |
| Defendant counsel | Dylan Raife | Attorney | Counsel for C. R. Bard, Inc.Search in Eureka ↗ |
| Defendant counsel | Janine Cone Metcalf | Attorney | Counsel for C. R. Bard, Inc.Search in Eureka ↗ |
| Defendant counsel | Jared W. Newton | Attorney | Counsel for C. R. Bard, Inc.Search in Eureka ↗ |
| Defendant counsel | Jason Alloy | Attorney | Counsel for C. R. Bard, Inc.Search in Eureka ↗ |
| Defendant counsel | Marc L. Kaplan | Attorney | Counsel for C. R. Bard, Inc.Search in Eureka ↗ |
| Defendant counsel | Matthew A. Traupman | Attorney | Counsel for C. R. Bard, Inc.Search in Eureka ↗ |
| Defendant counsel | Molly K. Moore | Attorney | Counsel for C. R. Bard, Inc.Search in Eureka ↗ |
| Defendant counsel | Nicole M. Smith | Attorney | Counsel for C. R. Bard, Inc.Search in Eureka ↗ |
| Defendant counsel | Scott Liscom Watson | Attorney | Counsel for C. R. Bard, Inc.Search in Eureka ↗ |
| Defendant counsel | Steven C. Cherny | Attorney | Counsel for C. R. Bard, Inc.Search in Eureka ↗ |
| Presiding judge | Judge J. P. Boulee | Chief Judge | Georgia Northern District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The court’s order adopts the magistrate’s Report and Recommendation on claim construction while overruling objections from both parties — indicating neither side fully prevailed on patent scope. The referral to private mediation, with a hard May 2024 deadline and an even cost split, is procedurally neutral. The administrative closure and stay of the remaining claim construction issue means no final judgment has entered; the case can be restored to the active docket. This verdict text does not resolve the infringement question and should not be read as a win or loss for either party.
US7278987B2 and five further patents — Foley catheter insertion kit technology
The lead patent, US7278987B2 (application US10/888659), covers technology in the Foley catheter insertion kit domain — a medical device category used widely in hospital and clinical settings for urinary catheterisation procedures. The assertion of early-filing patents US3329261A and US3978983A alongside more recent grants (US8678190B2, US8448786B2, US8631935B2) suggests Medline is protecting both foundational and iterative innovations in sterile catheter kit design and assembly. The multi-generational patent stack is consistent with a strategy to create overlapping claim coverage across the product lifecycle.
Foley catheter kits represent a high-volume, cost-sensitive segment of the hospital supply market where marginal design differences can carry significant patent risk. Medline’s decision to assert six patents against Bard’s SureStep product suggests confidence in the breadth of its IP position. For competitors in this segment — including kit assemblers, OEM suppliers, and GPO-contracted distributors — the outcome of claim construction in this case may inform which design features are considered within or outside the scope of Medline’s portfolio. Until the case is fully resolved, the full scope of enforceable claims remains uncertain.
Should you run an FTO analysis against Medline’s Foley catheter kit patents?
Any manufacturer, distributor, or private-label supplier of Foley catheter insertion kits — particularly those with products structurally similar to the SureStep Foley Kit — should treat this case as a prompt for an FTO review. With six patents asserted and claim construction still unresolved at the time of administrative closure, the enforceable scope of Medline’s IP position is not yet settled. This creates material risk for product teams planning new kit configurations or procurement teams evaluating alternative suppliers.
PatSnap Eureka’s FTO Search Agent can map your product’s technical features against the claim language of US7278987B2, US8678190B2, US8448786B2, and US8631935B2 in one workflow — flagging claims that may read on your design and identifying prior art that could support non-infringement or invalidity arguments. Claim monitoring alerts will notify you if any of these patents are amended, reexamined, or cited in new litigation, keeping your risk assessment current as this dispute evolves.
Run a freedom-to-operate analysis on US7278987B2 to assess your product’s exposure
Run FTO in Eureka →Similar patent infringement cases in catheter and medical procedure kit technology
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the Foley catheter and medical device IP landscape
A six-patent assertion by Medline against Bard underscores the competitive intensity of the disposable catheter kit segment and the risks of claim construction battles.
Six-patent stacking signals aggressive IP enforcement strategy
Asserting six patents simultaneously across a single accused product category is consistent with a portfolio enforcement strategy designed to maximise licensing leverage and complicate defendant invalidity arguments. Companies operating in the Foley catheter or broader single-use procedure kit market should audit competitor patent portfolios for overlapping claim scope before launching new SKUs.
Claim construction disputes in multi-patent cases raise settlement probability
When both parties object to a magistrate’s claim construction recommendation, it typically signals genuine uncertainty about patent scope — and uncertainty on both sides historically correlates with higher settlement rates. The court’s observation that issues were ‘somewhat narrowed’ before ordering mediation suggests the claim construction process served its filtering function even without producing a decisive winner.
Medline v C. — key questions answered
Medline asserted six patents: US7278987B2, US3329261A, US3978983A, US8678190B2, US8448786B2, and US8631935B2 — all relating to Foley catheter insertion kit technology. The accused product was identified as Bard’s SureStep Foley Kit.
The case was not dismissed and no final judgment was entered. Judge Boulee adopted a magistrate’s claim construction Report and Recommendation, then referred the parties to private mediation with a deadline of May 20, 2024. The case was administratively closed pending mediation. The public record does not confirm whether a settlement was reached.
Administrative closure removes a case from the court’s active docket but does not terminate it. The court retains jurisdiction and the case can be restored if mediation fails. No final judgment enters, meaning all asserted patent claims remain live and no estoppel effects attach. It is a procedural efficiency measure, not a ruling on the merits.
A magistrate judge issued a Report and Recommendation on claim construction. Both Medline and C. R. Bard filed objections, which Judge Boulee overruled. The court adopted the R&R as its order, finding that the issues had been ‘somewhat narrowed,’ which it cited as a basis for believing mediation would be productive. An outstanding claim construction issue was stayed pending mediation.
Yes. Because the case was administratively closed rather than dismissed, and no final judgment was entered, the six Medline patents asserted in this action remain potentially enforceable against the SureStep Foley Kit and related products. Companies with similar products should monitor the case status and consider an FTO review against the asserted patents.
PatSnap Eureka searches patents and litigation data to answer instantly.